Rapport Therapeutics financials
$33.02−1.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$125.1M | -$83.1M |
| Net income | -$111.5M | -$78.3M |
| Net margin | — | — |
| Diluted EPS | $-2.86 | $-3.78 |
| EBITDA | -$124.1M | -$82.2M |
| Operating cash flow | -$87.5M | -$64.8M |
| Free cash flow | -$88.1M | -$67.2M |
| Diluted shares | 38.9M | 20.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $52.6M | $56.8M |
| Short-term investments | $437.9M | $248.5M |
| Total debt | $0.00 | $0.00 |
| Total assets | $512.4M | $314.9M |
| Total liabilities | $27.8M | $9.5M |
| Shareholders' equity | $484.7M | $305.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology